GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Next Science Ltd (ASX:NXS) » Definitions » Forward PE Ratio

Next Science (ASX:NXS) Forward PE Ratio : 0.00 (As of Jun. 07, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Next Science Forward PE Ratio?

Next Science's Forward PE Ratio for today is 0.00.

Next Science's PE Ratio without NRI for today is 0.00.

Next Science's PE Ratio for today is 0.00.


Next Science Forward PE Ratio Historical Data

The historical data trend for Next Science's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Next Science Forward PE Ratio Chart

Next Science Annual Data
Trend 2020-12 2021-12 2022-12
Forward PE Ratio
129.87 58.48 8.03

Next Science Semi-Annual Data
2021-09 2021-12
Forward PE Ratio 64.94 58.48

Competitive Comparison of Next Science's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Next Science's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Next Science's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Next Science's Forward PE Ratio falls into.



Next Science Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Next Science  (ASX:NXS) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Next Science Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Next Science's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Next Science (ASX:NXS) Business Description

Traded in Other Exchanges
Address
821 Pacific Highway, Suite 1902, Level 19, Tower A, The Zenith Building, Chatswood, NSW, AUS, 2067
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from the U.S. and Australia, of which prime revenue is derived from the U.S.

Next Science (ASX:NXS) Headlines

No Headlines